Munasinghe et al., 2022 - Google Patents

Immuno-dominant dengue NS1 peptides as antigens for production of monoclonal antibodies

Munasinghe et al., 2022

View HTML
Document ID
6519300452184393303
Author
Munasinghe E
Athapaththu M
Abeyewickreme W
Publication year
Publication venue
Frontiers in Molecular Biosciences

External Links

Snippet

Synthetic peptides have recently become common as antigens for antibody production. Peptides are short chains of amino acids that can be used to elicit an immune response. The immunogenicity of the peptide antigens varies depending on the length, charge, solubility …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Similar Documents

Publication Publication Date Title
Flyak et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region
Khan et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2
JP7536059B2 (en) Antibody-Mediated Neutralization of Chikungunya Virus
CN105228649B (en) HCV antigen-antibody combination assays and methods and compositions for use therein
KR100847586B1 (en) How to measure hepatitis C virus
Li et al. Generation of antibodies against COVID-19 virus for development of diagnostic tools
CN1871518B (en) Method for detecting hepatitis C virus
JPWO2000007023A1 (en) Hepatitis C virus detection method
Sunwoo et al. Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassay
Chattopadhyay et al. Development and characterization of monoclonal antibody against non-structural protein-2 of Chikungunya virus and its application
WO2021209824A1 (en) Methods and products for serological analysis of sars-cov-2 infection
WO2013043125A1 (en) Enterovirus 71 specific antibodies and uses thereof
KR102008609B1 (en) Hybridomas that produce specific antibodies to non-structural protein 1 of Zika virus and antibodies produced therefrom, and uses thereof
KR102012123B1 (en) Hybridomas that produce specific antibodies that bind simultaneously to non-structural protein 1 of dengue virus and Zika virus and antibodies produced therefrom, and uses thereof
Munasinghe et al. Immuno-dominant dengue NS1 peptides as antigens for production of monoclonal antibodies
CN107921123A (en) Camel source single domain HCV antibody and application method
Lei et al. High-affinity VNARs targeting human hemoglobin: Screening, stability and binding analysis
Chen et al. A secreted form of the hepatitis E virus ORF2 protein: design strategy, antigenicity and immunogenicity
JP2006067979A (en) Immunity detecting method for influenza a type virus
CN101863975B (en) HBV (Hepatitis B Virus) preS1 B cell epitope peptide, hybridoma cell strain prepared by same and application
CN116990507B (en) A method for early screening of monkeypox virus infection
Xi et al. Prokaryotic expression of hepatitis C virus-NS3 protein and preparation of a monoclonal antibody
TWI737918B (en) Anti-dengue virus antibodies and applications thereof
León‐Juárez et al. Generation and characterization of a monoclonal antibody that cross‐reacts with the envelope protein from the four dengue virus serotypes
Vidal-Alcántara et al. Production and characterization of monoclonal antibodies for the detection of the hepatitis C core antigen